Melanoma

E1609 Phase III Randomized Study of Adjuvant Ipilimumab Versus High-Dose Recombinant Interferon Alfa-2b in Patients With High-Risk Stage IIIB, IIIC, or IV Melanoma

Please contact the NYOH Research Department for more information on clinical trials at (518) 489-0044 ext. 1239